HDV Emerging Agents

CE / CME

Rational Use of New and Emerging Agents for Hepatitis Delta Virus

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: March 16, 2022

Expiration: March 15, 2023

Heiner Wedemeyer
Heiner Wedemeyer, MD
Cihan Yurdaydin
Cihan Yurdaydin, MD

Activity

Progress
1
Course Completed

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:

  • Assembly inhibitors (eg, lonafarnib)
  • Entry inhibitors (eg, bulevirtide)
  • Interferon lambda
  • Nucleic acid polymers
  • Small interfering RNA (siRNA) agents